News

AstraZeneca posted a net income of $2.77bn for the first quarter of 2010, compared to $2.14bn for the prior year period. Operating income was $3.64bn, compared to $3.16bn

Galapagos’ service division BioFocus is expected to perform the research and eligible to receive $41m (EUR31m) in research fees during the five-year collaboration. BioFocus is expected to apply

LifeCodexx aims to establish ‘Next Generation Molecular Diagnostics’ in Europe. This will provide improved diagnostics for targeted, cost-efficient treatments. The test development currently being undertaken also receives public

In a double-blind, active-controlled Phase II study of 480 randomised subjects, the safety, tolerability and immunogenicity of a single 15microgram dose or 60microgram dose (per strain) of trivalent

Applied BioCode’s Barcoded Magnetic Beads digital multiplexing technology, along with the BioCode-1000 Analyzer for barcode and fluorescence detection, results in a flexible digital multiplexing platform suited for a

Roche’s T-emerge Phase III clinical trials are designed as multicenter, multi-country, randomized, controlled (active or placebo), double-blind and open studies. Over 6,000 patients will be enrolled in the

Sanofi-aventis has posted business net income of EUR2.43bn, or E1.86 per diluted share, compared to EUR2.21bn, or EUR1.70 per diluted share, for the prior year period. Business operating

Oncos Therapeutics said that after treating 200 late stage cancer patients since 2007 with safety and efficacy results, it has selected its modified oncolytic adenovirus CGTG-102 as its

pSivida’s Iluvien is an injectable, non-erodable, intravitreal implant for the treatment of DME, a potentially blinding condition that affects approximately one million people in the US. Iluvien is